Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-10-03
2006-10-03
Jiang, S. Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S049000, C514S051000
Reexamination Certificate
active
07115584
ABSTRACT:
The present invention discloses a method for treating HIV that includes administering β-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 or the 172 codons of the reverse transcriptase region. Also disclosed is a method for using β-D-D4FC as “salvage therapy” to patients which exhibit drug resistance to other anti-HIV agents. β-D-D4FC can be used generally as salvage therapy for any patient which exhibits resistance to a drug that induces a mutation at other than the 70(K to N), 90 or the 172 codons.
REFERENCES:
patent: 3817982 (1974-06-01), Verheyden et al.
patent: 4522811 (1985-06-01), Eppstein
patent: 4725442 (1988-02-01), Haynes
patent: 4788181 (1988-11-01), Driscoll et al.
patent: 4891225 (1990-01-01), Langer
patent: 4963662 (1990-10-01), Matthes et al.
patent: 5034394 (1991-07-01), Daluge
patent: 5196438 (1993-03-01), Martin et al.
patent: 5366972 (1994-11-01), Hargrave et al.
patent: 5409810 (1995-04-01), Larder
patent: 5413999 (1995-05-01), Vacca et al.
patent: 5463092 (1995-10-01), Hostetler
patent: 5484926 (1996-01-01), Dressman et al.
patent: 5489593 (1996-02-01), Palmer et al.
patent: 5496935 (1996-03-01), Matthes et al.
patent: 5519021 (1996-05-01), Young et al.
patent: 5561120 (1996-10-01), Lin et al.
patent: 5563142 (1996-10-01), Palmer et al.
patent: 5585397 (1996-12-01), Tung et al.
patent: 5604209 (1997-02-01), Ubasawa et al.
patent: 5627160 (1997-05-01), Lin et al.
patent: 5631239 (1997-05-01), Lin et al.
patent: 5703058 (1997-12-01), Schinazi et al.
patent: 5756478 (1998-05-01), Cheng et al.
patent: 5869461 (1999-02-01), Cheng et al.
patent: 5905070 (1999-05-01), Schinazi et al.
patent: 6232300 (2001-05-01), Schinazi et al.
patent: 6391859 (2002-05-01), Schinazi et al.
patent: 1620047 (1970-03-01), None
patent: 0 409 227 (1991-01-01), None
patent: 0515156 (1992-11-01), None
patent: 0519464 (1992-12-01), None
patent: 8901258 (1990-12-01), None
patent: WO 91/06554 (1991-05-01), None
patent: WO 91/09849 (1991-07-01), None
patent: WO91/09849 (1991-07-01), None
patent: WO 91/16333 (1991-10-01), None
patent: WO 91/19727 (1991-12-01), None
patent: WO 94/14456 (1994-07-01), None
patent: WO 94/27616 (1994-12-01), None
patent: WO 95/07287 (1995-03-01), None
patent: WO 96/22778 (1996-08-01), None
patent: WO 96/28170 (1996-09-01), None
patent: WO 99/66936 (1999-12-01), None
(S) Romero et al., “Bis(heteroaryl)piperazine (BHAP) Reverse Transcriptase Inhibitors:” . . . , a Second Generation Clinical Candidate, Journal of Medicinal Chemistry, 36(10), 1505-1508 (May 14, 1993).
EPO Search Report for SN. 96 902772, Jul. 26, 1999.
Romero et al., “Bis(heteroaryl)piperazine (BHAP) Reverse Transcriptase Inhibitors:” Structure-Activity Relationships of Novel Substituted Indole Analogues and the Identification of 1-[(5-Methansulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1-methylethyl)amino]pyridinyl]piperazine Monomethanesulfonate (U-90152SS), a Second Generation Clinical Candidate,Journal of Medicinal Chemistry, 36(10), 1505-1508 (May 14, 1993).
Ajmera, S., et al.,J. Med. Chem., 27(1):11-14 (1984), Month of publication data not supplied or could not be determined from copy supplied.
Balzarini, J et al.,Biochem. And Biophys. Res. Comm., 164(3): (1989)(Nov. 15, 1989).
Chang, C., et al.,J. of Med. Chem., 267(20):13938-13942 (1992). (Jul. 15, 1992).
Chen, S H et al., Synthesis and comparative evaluation of two antiviral agents: beta-L-Fd4C and beta-D-Fd4C,Bioorganic&Medicinal Chemistry Letters, GB, Oxford, 8(22):3245-3250 (Nov. 17, 1998).
Choi, W. et al.,Biorganic&Med. Chem. Letters, 3(4):693-696 (1993), Month of publication data not supplied or could not be determined from copy supplied.
Coe, P.L.. et al.,J. Flourine Chem., 69(1):19-24 (1994), Month of publication data not supplied or could not be determined from copy supplied.
Doong, S., et al.,Proc. Natl. Acad. Sci.(USA), 88:8495-8499 (1991). (Oct. 1991).
Frick, L.W., et al.,AntiMicrob. Agents and Chemotherapy, 37(11):2285-2292 (Nov. 1993).
Hammer, S.M., “Advances in antiretroviral therapy and viral monitoring,”AIDS, 10(3):s1-s11 (1996), Month of publication data not supplied or could not be determined from copy supplied.
Horwitz, J.P., et al.,Tetrah. Letters, 1964(38):2725-2727, (1964), Month of publication data not supplied or could not be determined from copy supplied.
Hronowski, L.J.J., et al.,Can. J. Chem., 70(4):1162-1169 (1992), Month of publication data not supplied or could not be determined from copy supplied.
Izuta, S., et al.,Nucleic Acids Symp. Ser.(Symp. Nucleic Acids Chem., 13th) 241-244 (1985)(Nov. 6, 1985).
Jeong, L.S., et al.,J. of Med. Chem., 36(2):181-195 (1993). (Jan. 22, 1993).
Khwaja, T.A., et al.,J. Med. Chem., 10(6):1066-1070 (1967). (Nov. 1967).
Kim, H.O., et al.,J. of Med. Chem., 36(5):519-528 (1993). (Mar. 5, 1993).
Larder, B.A., et al.,Science, 243:1731-1734 (1989). (Mar. 31, 1989).
Mellors, J, W, et al.,Mol. Pharm., 41:446-451 (1992 ). (Jan. 1992).
Nunberg, J.H., et al.,J. Virol. I, 65(9):4887-4892 (1991).(Sep. 1991).
Richman, D., et al.,Proc. Natl. Acad. Sci.(USA), 88:11241-11245 (1991). (Dec. 1991).
Schinazi, R.F. et al.,AntiMicrob. Agents and Chemotherapy, 36(11):2423-2431 (1992). (Nov. , '92).
Schinazi, R.F. et al.,AntiMicrob. Agents and Chemotherapy, 38(9):2172-2174 (1994). (Sep. 1994).
Schinazi, R.F., et al., “Mutations in retroviral genes associated with drug resistance: 2000-2001 update”International Antiviral News8(5): 65-91 (2000). (May 2000).
Schinazi, R.F., et al.,Biochem. Pharma., 44(2):199-204 (1992), Month of publication data was not supplied or could not be determined from the copy supplied.
Shigeta, S., et al.,J. Infect. Dis., 163(2):270-275 (1991). (Feb. 1991).
Siddiqui, M.A., et al.,J. Med. Chem., 35(12):2195-2201 (1992), Month of publication data was not supplied or could not be determined from the copy supplied.
St. Clair, M.H., et al.,Science, 253:1557-1559 (1991). (Sep. 27, 1991).
Van Aerschot, A., et al.,J. of Med. Chem., 33:1833-1839 (1990), Month of publication data was not supplied or could not be determined from the copy supplied.
Van Draanen, N.A. et al.,AntiMicrob. Agents and Chemotherapy38(4):868-871 (1994). (Apr. , 1994).
Wilson, L.J., et al.,Biorganic&Med. Chem. Letter, 3(2):169-174 (1993), Month of publication data was not supplied or could not be determined from the copy supplied.
Hammond Jennifer L.
Liotta Dennis C.
Mellors John W.
Schinazi Raymond F.
Crane L. E.
Emory University
Jiang S. Anna
King & Spalding LLP
Knowles, Esq. Sherry M.
LandOfFree
HIV-1 mutations selected for by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV-1 mutations selected for by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV-1 mutations selected for by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3704802